• GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months

    1 month ago - By Xconomy

    GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental therapies to clinical testing this summer. The partnership will leverage antibody technology from Vir and genomics expertise from GSK. The companies will work together to develop drugs and vaccines for the novel coronavirus. According to financial terms of the preliminary agreement, GSK will acquire shares of its San Francisco-based partner at the price of $37.73 each, which is a 10 percent premium to...
    Read more ...